During the 23rd ANDI Health Forum held in Cartagena, Colombia from 8th to 10th of June, 2016, ANDI, the National Association of Colombian Industries, presented its New Ethical Code of Transparency.
The Congress was a total success this year. It gathered 1 300 people which represents an increase of 30% compared to last year and shows a great interest from the public and private parties.
No doubt this Healthcare Congress has become the most relevant event of the sector in Colombia. It gathered representatives from the healthcare sector such as pharmaceutical companies, HCPs and healthcare organizations or services providers.
The main subject highlighted during the congress was transparency, illustrating the increasing importance of this theme in Colombia and reaffirming the country’s leadership in Latin-America in terms of transparency and compliance.
The ANDI´s Pharmaceutical Chamber took advantage of this event to give the Government the New Ethical Code of Transparency which was approved in May by all the Pharmaceutical Chamber members in coordination with AFIDRO, the national Association of Pharmaceutical Laboratories for Research and Development, who had its own Ethical Code of Transparency since January 2015.
Dr. Emilio Sardi, President of the Pharmaceutical Chamber of ANDI, presented the Ethical Code of Transparency. During his lecture, he encouraged the pharma sector to adapt its business processes to the requirements exposed in the New Ethical Code, improving transparency in the interactions between pharmaceutical companies and healthcare professionals.
The second big topic of the Congress focused on the efficiency of healthcare models through cooperation between the Government, the pharmaceutical industry, healthcare services providers (EPS) and healthcare Professionals and Hospitals (IPS).
Colombia has one of the most complex healthcare systems in the world which has been very criticized in public opinion and has also created serious situations of debt among EPS.
Historically there have been strong rivalries between local pharmaceutical industries and international ones due to drug approvals or arguments about price regulation. This context has divided the industry between two associations: ASINFAR, representing the national companies, and AFIDRO, representing the international ones.
To carry out the new transparency regulations there are no divisions between national and international companies. Both associations are supporting the Pharmaceutical Chamber of ANDI in the presentation and use of the code. ANDI is currently cooperating with the Government so that the code can be applied very soon.